E78.011

Heterozygous familial hypercholesterolemia [HeFH]

Billable FY2026 2025-10-01 → 2026-09-30 FY2026–2027 only

Exclusions 8 never code together

E78code

Excludes1

Excludes1

androgen insensitivity syndrome (E34.5-)E34.5-
congenital adrenal hyperplasia (E25.0)E25.0
hemolytic anemias attributable to enzyme disorders (D55.-)D55.-
Marfan syndrome (Q87.4-)Q87.4-
5-alpha-reductase deficiency (E29.1)E29.1

Excludes2

Excludes1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)P70-P74

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 1

Notes

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.E05.8 E07.0 E16-E31 E34.-

Index entries leading here 3

Cholesterolemia (essential) (pure) E78.00
- familial E78.019
  - heterozygous E78.011
Hypercholesterolemia (essential) (primary) (pure) E78.00
- familial E78.019
  - heterozygous [HeFH] E78.011
HeFH (heterozygous familial hypercholesterolemia) E78.011

Alongside this code 2 same parent — E78.01

Additional references

AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Present FY2026–FY2027.